Skip to content
Screener

NovoCure NVCR Shares (Diluted)

Shares (Diluted) at other companies

Boston Scientific logo
Boston ScientificBSX
1.5B-1.3%
Medtronic logo
MedtronicMDT
1.3B-0.1%
Nuvation Bio logo
Nuvation BioNUVB
348.8M+2.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
450.2M+34.6%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
100.6M+12.8%
AngioDynamics logo
AngioDynamicsANGO
41.5M+1.6%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025Year ended December 31,2025
Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share$(15,658)$(40,139)$(86,796)$(74,458)$(136,227)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share116,012,397111,572,191115,106,850110,930,576111,471,991
Potentially anti-dilutive shares that were excluded from the computation of basic net income (loss) per share:
Options8,345,0389,069,4608,945,7468,902,5499,297,875
RSUs and PSUs4,293,9244,365,0343,964,3274,899,2734,781,731
ESPP187,717141,192187,717141,192208,854
Weighted anti-dilutive shares outstanding which were not included in the diluted calculation12,826,67913,575,68613,097,79013,943,01414,288,460
Basic and diluted net income (loss) per ordinary share$(0.13)$(0.36)$(0.75)$(0.67)$(1.22)

Item 1. Financial Statements

FAQ

What is NovoCure's shares (diluted)?
NovoCure (NVCR) reported shares (diluted) of 116M in Q2 2026.
How has NovoCure's shares (diluted) changed year-over-year?
NovoCure's shares (diluted) increased by 4.0% year-over-year, from 111.6M to 116M.
What is the long-term trend for NovoCure's shares (diluted)?
Over 4 years (2021 to 2025), NovoCure's shares (diluted) has grown at a 1.9% compound annual growth rate (CAGR), from 413.7M to 445.2M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about NovoCure's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude